The First and Only One Year CGM For Confident Clinical Decisions

<p>One CGM. One Year of Minimal Disruptions.<sup>1-3</sup></p>

One CGM. One Year of Minimal Disruptions.1-3

The longest lasting and most
dependable CGM1-3

<p>Exceptional Accuracy Over<br />One Year<sup>1</sup></p>

Exceptional Accuracy Over
One Year1

The most accurate CGM in the hypoglycemic range1-3 and essentially no compression lows4

<p>Designed for Improved<br />Quality of Life

</p>

Designed for Improved
Quality of Life



No more frequent CGM changes and wasted
sensors1-3

Eversense 365 – One CGM.
One Year of Minimal Disruptions.

Tiny sensor placed under the skin and stays secure for one year

If knocked-off, the removable* transmitter can be immediately put right back on

The Most Dependable CGM1-3

% Sensors Lasting their Full Lifetime

Eversense 365 90% 365 days
Dexcom G7 80.5% 10 days
Libre 3 68.3% 14 days
0 20 40 60 80 100

Consistent and Reliable Accuracy1

Exceptional Accuracy over One Year1

8.8%

Overall MARD

Less than 10% MARD at every stage of sensor life, providing you with clinical confidence. Now with only 1 calibration per week (after day 13)1

Most Accurate in Low Glucose Ranges1-3

Eversense 365 7.7
Dexcom G7 16.0
Libre 3 14.2


MAD (mg/dL)
Severe Hypoglycemic Range MAD
<54mg/dL for all

Essentially No Compression Lows4

Percent within 15/15% reference

No Sensor Compression 85.7%
With Compression 86.1%

Accuracy was not affected by compression

Ready to Get Started?

Ready to start prescribing? Learn how simple it can be. Learn how to become an Eversense Inserter.

this is 50 | 50 image

* There is no glucose data generated when the transmitter is removed

1. Senseonics. (2024) Eversense 365 Continuous Glucose Monitoring System User Guide. LBL-7702-01-001 Rev A
2. Dexcom (2024) G7 User Manual AW00078-10 Rev 003 MT-00078-10
3. Abbott. (2024) Freestyle Libre 3 Continuous Glucose Monitoring System User Guide ART49385-001 Rev. A 04/24
4. Christiansen MP et al. (2018) A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. DIABETES TECHNOLOGY & THERAPEUTICS, 20(3):197-206
5. Deiss, D. et al. (2020). Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: A post-market registry study. Diabetes Technology and Therapeutics, 22(1), 48–52. https://doi.org/10.1089/dia.2019.0159

Disclaimer

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.

The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.

For important safety information, see bit.ly/eversensesafety

Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.

 

PP-SENS-365-GBL-0027